Abstract
Recently, the use of astemizole and terfenadine, both non-sedating H1-antihistamines, caused considerable concern. Several case reports suggested an association of both drugs with an increased risk of torsades de pointes, a special form of ventricular tachycardia. The increased risk of both H1-antihistamines was associated with exposure to supratherapeutic doses; for terfenadine the risk was also associated with concomitant exposure to the cytochrome P-450 inhibitors ketoconazole, erythromycin and cimetidine. To predict the size of the population that runs the risk of developing this potentially fatal adverse reaction in the Netherlands, the prevalence of prescribing supratherapeutic doses and the concomitant exposure to terfenadine and cytochrome P-450 inhibitors was studied. Data were obtained from the PHARMO data base in 1990, a pharmacy-based record linkage system encompassing a catchment population of 300,000 individuals. The results of the study showed that the prescribing of supratherapeutic doses and the concomitant exposure to terfenadine and cytochrome P-450 inhibitors was low. Furthermore, the results of a sensitivity analysis showed that the risk of fatal torsades de pointes has to be as high as 1 in 10,000 to cause one death in the Netherlands in one year.
Similar content being viewed by others
References
Herings RMC. Patterns of long term drug use in The Netherlands. In: Bakker A, Hekster YA, Leufkens HGM, editors. Drug consumption in The Netherlands. Noordwijk: Amsterdam Medical Press, 1991:50–8.
Lunde I. Antihistamines (H1-receptor antagonists). In: Dukes MNG, editor. Meyler's side effects of drugs. 11th ed. Amsterdam: Elsevier Scientific Publishers, 1988:316–21.
Craft TM. Torsade de pointes after astemizole overdose. BMJ 1986;292(6521):660.
Snook J, Boothman-Burrell D, Watkins J, Colin-Jones D. Torsade de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract 1988;42(6):257–9.
Simons FE, Kesselman MS, Giddins NG, Pelech AN, Simons KJ. Astemizole-induced torsade de pointes [letter]. Lancet 1988;2(8611):624.
Bishop RO, Gaudry PL. Prolonged Q-T interval following astemizole overdose. Arch Emerg Med 1989;6(1):63–5.
Leor J, Harman M, Rabinowitz B, Mozes B. Giant U waves and associated ventricular tachycardia complicating astemizole overdose: successful therapy with intravenous magnesium [letter]. Am J Med 1991;91(1):94–7.
Hoppu K, Tikanoja T, Tapanainen P, Remes M, Saarenpaeae-Heikkilae O, Kouvalainen K. Accidental astemizole overdose in young children. Lancet 1991;338(8766):538–40.
Clarke A, Love H. Astemizole-induced ventricular arrhythmias: an unexpected cause of convulsions. Int J Cardiol 1991;33(1):165–7.
Tobin JR, Doyle TP, Ackerman AD, Brenner JI. Astemizole-induced cardiac conduction disturbances in a child. JAMA 1991;266(19):2737–40.
Wiley JF 2d, Gelber ML, Henretig FM, Wiley CC, Sandhu S, Loiselle J. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992;120(5):799–802.
Safety of terfenadine and astemizole. Med Lett Drugs Ther 1992;34(863):9–10.
Torsades de pointes due to H1 antihistamines. Cases reported following astemizole and terfenadine overdose or drug interactions. Rev Prescr 1992;1:119.
Krasner LM. Terfenadine use associated with ventricular dysrhythmias. Crit Care Nurse 1992;12(2):51–2.
Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 1990;264(21):2788–90.
Mathews DR, McNutt B, Okerholm R, Flicker M, McBride G. Torsades de pointes occurring in association with terfenadine use [letter]. JAMA 1991;266(17):2375–6.
Eller MG, Okerholm RA. Pharmacokinetic interaction between terfenadine and ketoconazole. Clin Pharmacol Ther 1991;49:130.
Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazarra R. The long QT syndromes. A critical review, new clinical observations and a unifying hypothesis. Cardiovasc Dis 1988;31:115–72.
Cloud J, Deveny K. FDA Orders strong warning on Seldane use. Wall Street Journal West Coast Edition 1992;Jul 8:6.
HHS News. Press release concerning the safety of Hismanal (July 20).
Anatomical Therapeutic Chemical (ATC) index, including defined daily doses (DDD) for plain substances. Oslo: World Health Organization, 1992.
SAS. SAS 6.03 Guide. Carry: SAS Institute, 1988.
Fox Software. FOXPRO 2.0. Perrysburg: Fox Software, 1991.
Lunde PKM, Baksaas I, Halse M, Halvorsen IK, Stromnes B, Oydvin K. The methodology of drug utilization studies. In: Bergman U, Wahba AHW, Grimsson A, Westerholm B, editors. Studies in drug utilization. Copenhagen: World Health Organization, 1979:17–28.
Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 1989;298(6669):325.
Van der Kuy A, editor. Farmacotherapeutisch Kompas 1992 [Pharmacotherapeutic Compass 1992]. Amstelveen: Ziekenfondsraad, 1992.
Bast A, Saveijne-Chapel EM. Inhibition of monoxygenase and oxidase activity in rat-hepatic cytochrome P450 by H2 inhibitors. Xenobiotica 1984;14:399–408.
Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford: Blackwell Scientific Publications, 1987:59.
Nordic statistics on medicine 1987–1989. Comparison of total drug consumption in the Nordic countries. Uppsala: Nordic Council on Medicines, 1991.
Wilson JD, Braunwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci AS, et al., editors. Harrison's principles of internal medicine. 12th ed. New York: McCraw Hill, 1991.
Brandon ML. Newer non-sedating antihistamines. Will they replace older agents? Drugs 1985;30:377–81.
Ahmad SR. USA: Antihistamines in cold remedies [letter]. Lancet 1992;339:1045.
Advenier C, Queille-Roussel C. Rational use of antihistamines in allergic dermatological conditions. Drugs 1989;38(4):634–44.
Warin RP. Torsades de pointes complicating treatment with terfenadine [letter]. BMJ 1991;303(6793):58.
Stricker BHCh, Prins AMA, Schilte PPM. Ernstige psychische bijwerkingen bij kinderen door gebruik van hoge doseringen deptropine [Serious psychic effects of large doses of deptropine in children]. Ned Tijdschr Geneeskd 1992; 136(28):1362–5.
Rinder CF, D'Amato SL, Rinder HM, Cox PM. Survival in complicated diphenhydramine overdose. Crit Care Med 1988;16(11):1161–2.
Von Muehlendahl KE, Krienke EG. Zur Toxizität von Cypro-heptadin (Nuran). Nebenwirkungen und akzidentielle Intoxikationen [Toxicity of cyproheptadine. Side effects and accidental overdosage]. Monatsschr Kinderheilkd 1978; 126(3):123–6.
Hestand HE, Teske DW. Diphenhydramine hydrochloride intoxication. J Pediatr 1977;90(6):1017–8.
De Jonge GA. Wiegedood en promethazine [Sudden infant death syndrome and promethazine]. Ned Tijdschr Geneeskd 1992;136(40):1945–8.
Kahn A, Blum D. Phenothiazine and sudden infant death syndrome. Pediatrics 1982;70:75–8.
Loratadine [Dear Doctor Letter]. Amstelveen: Schering-Plough 1992;Nov 12.
Richards DM, Brogden RN, Heel RC, Speight TM, Avery GS. Astemizole: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1984;28:38–61.
Sorkin EM, Heel RC. Terfenadine: A review of its pharmaco-dynamic properties and therapeutic efficacy. Drugs 1985;29:34–56.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Herings, R.M.C., Stricker, B.H.C., Leufkens, H.G.M. et al. Public health problems and the rapid estimation of the size of the population at risk. Pharm World Sci 15, 212–218 (1993). https://doi.org/10.1007/BF01880629
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01880629